Fusion Antibodies (FAB.L), the specialist in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, recently raised £1.4m (gross) via a placing and equity subscription of 11.1m shares at the then prevailing share price of 13p/share. The fundraising provides Fusion with the capital to implement a number of initiatives designed to accelerate its growth, following the launch of its OptiMAL® platform last month. We understand that the launch ha ....